Pazopanib + weekly paclitaxel vs weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer phase 2 trial

Lancet Oncology: abstract

 Background

Inhibition of angiogenesis is a valuable treatment strategy for ovarian cancer. Pazopanib is an anti-angiogenic drug active in ovarian cancer. We assessed the effect of adding pazopanib to paclitaxel for patients with platinum-resistant or platinum-refractory advanced ovarian cancer.

Interpretation

Our findings suggest that a phase 3 study of the combination of weekly paclitaxel plus pazopanib for patients with platinum-resistant or platinum-refractory advanced ovarian cancer is warranted.